OrthoSera — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OrthoSera is a Budapest-based regenerative medicine company pioneering the therapeutic use of blood serum and its components, particularly albumin, to activate stem cells and enhance tissue regeneration. Its lead product, BoneAlbumin—a serum albumin-enhanced bone allograft—has been in clinical use since 2015 with supporting long-term data. The company is developing a pipeline targeting osteoarthritis and skin rejuvenation while also applying its plasma expertise to areas like convalescent serum therapy. It maintains a fully integrated, quality-certified manufacturing and R&D operation.

OrthopedicsDentistryDermatologyOsteoarthritis

Technology Platform

Proprietary platform leveraging human blood serum and serum albumin as active biomaterials and therapeutic agents. Focuses on formulating serum derivatives to activate stem cells and enhance tissue regeneration, with applications in coating implants, creating composite materials, and plasma fractionation.

Opportunities

The global shift towards regenerative medicine and biologically advanced implants creates a large addressable market in orthopedics, dentistry, and aesthetics.

OrthoSera's first-mover advantage with a clinically validated serum-albumin product (BoneAlbumin) provides a revenue-generating foundation to fund pipeline development.

Its integrated GMP plasma and tissue processing capabilities could be leveraged for CDMO services or rapid response to future pathogen threats.

Risk Factors

The company faces significant clinical development risk in advancing its pre-clinical osteoarthritis and skin programs.

As a small, private company based in Hungary, scaling commercial operations internationally and competing with large, well-funded medtech and pharma players presents a major challenge.

Financial runway is likely limited, creating dependency on the success of early products and the ability to secure additional funding.

Competitive Landscape

OrthoSera competes in the bone graft substitute market with large orthobiologics companies (e.g., Medtronic, Stryker, Zimmer Biomet) and dental biomaterial firms. In osteoarthritis and skin rejuvenation, it faces competition from both pharmaceutical biologics (e.g., platelet-rich plasma, growth factors) and emerging cell/gene therapies. Its differentiation lies in its specific focus on serum albumin as a patented, active therapeutic biomaterial with clinical data.

More companies in Regenerative Medicine →More companies in Hungary →